Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 12/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 12/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 12/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 12/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 12/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25180369 | 1.00 | CHRM2 (0.54) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL26928055 | 0.94 | CHRM2 (0.57) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1819998 | 0.82 | CHRM2 (0.56) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3601162 | 0.82 | DPP4 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3526616 | 0.82 | DPP4 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2269972 | 0.82 | CHRM2 (0.56) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1819999 | 0.82 | CHRM2 (0.56) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL6234921 | 0.82 | DPP4 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL28541669 | 0.80 | DPP4 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1239549 | 0.80 | DPP4 (0.62) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| US-12441742-B2 | Naphthyridine compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| US-20240368152-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2024-11-07 | — | — | US | disclosed |
| EP-4415824-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2024-08-21 | — | — | EP | disclosed |
| CN-118525017-A | Quinoline compounds as KRAS inhibitors | 因赛特公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20240101557-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS | INCYTE CORPORATION | 2024-03-28 | — | — | US | disclosed |
| US-11939328-B2 | Quinoline compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2024-03-26 | — | — | US | disclosed |
| WO-2024015731-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS | INCYTE CORPORATION (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230174555-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-06-08 | — | — | US | disclosed |
| US-20230174555-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-06-08 | — | — | US | disclosed |
| US-20230174555-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-06-08 | — | — | US | disclosed |
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-05-11 | — | — | US | disclosed |
| WO-2023064857-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023034290-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441742-B2 | Naphthyridine compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | CHRM2 4866/4885CHRM4 4876/4885CHRM5 4882/4885 |
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | CHRM2 4782/4885CHRM4 4856/4885CHRM5 4863/4885 |
| US-20240368152-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | CHRM2 4782/4885CHRM4 4856/4885CHRM5 4863/4885 |
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | CHRM2 4782/4885CHRM4 4856/4885CHRM5 4863/4885 |
| US-20230174555-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | CHRM2 4866/4885CHRM4 4876/4885CHRM5 4882/4885 |
| US-20240101557-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS | KRAS, NRAS, HRAS | CHRM2 4857/4885CHRM4 4877/4885CHRM5 4885/4885 |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | CHRM2 4782/4885CHRM4 4856/4885CHRM5 4863/4885 |
| US-11939328-B2 | Quinoline compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | CHRM2 4782/4885CHRM4 4856/4885CHRM5 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.